Heidelberg Pharma Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Andreas Pahl

Chief Executive Officer (CEO)

€328.3k

Compensación total

Porcentaje del salario del CEO	73.1%
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	1.1yrs
Promedio de permanencia en la Junta Directiva	11.9yrs

Actualizaciones recientes de la dirección

Recent updates

Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?

Feb 16

Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues

Dec 05

Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%

Jul 21

Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%

Jan 17

We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

Dec 14

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Andreas Pahl en comparación con los beneficios de Heidelberg Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Feb 29 2024	n/a	n/a	-€18m
Nov 30 2023	n/a	n/a	-€20m
Aug 31 2023	n/a	n/a	-€22m
May 31 2023	n/a	n/a	-€27m
Feb 28 2023	n/a	n/a	-€19m
Nov 30 2022	€328k	€240k	-€20m
Aug 31 2022	n/a	n/a	-€21m
May 31 2022	n/a	n/a	-€22m
Feb 28 2022	n/a	n/a	-€27m
Nov 30 2021	€442k	€240k	-€26m
Aug 31 2021	n/a	n/a	-€25m
May 31 2021	n/a	n/a	-€22m
Feb 28 2021	n/a	n/a	-€20m
Nov 30 2020	€295k	€207k	-€18m
Aug 31 2020	n/a	n/a	-€17m
May 31 2020	n/a	n/a	-€15m
Feb 29 2020	n/a	n/a	-€12m
Nov 30 2019	€288k	€200k	-€10m
Aug 31 2019	n/a	n/a	-€10m
May 31 2019	n/a	n/a	-€11m
Feb 28 2019	n/a	n/a	-€12m
Nov 30 2018	€286k	€200k	-€12m
Aug 31 2018	n/a	n/a	-€11m
May 31 2018	n/a	n/a	-€11m
Feb 28 2018	n/a	n/a	-€11m
Nov 30 2017	€241k	€171k	-€11m

Compensación vs. Mercado: La compensación total ($USD351.17K) de Andreas está en línea con el promedio de empresas de tamaño similar en el mercado German ($USD406.99K).

Compensación vs. Ingresos: La compensación de Andreas ha sido consistente con los resultados de la empresa en el último año.

CEO

Andreas Pahl

less than a year

Permanencia

€328,276

Compensación

Prof. Dr. Andreas Pahl is Chief Executive Officer & Spokesman of the Executive Board at Heidelberg Pharma AG since February 1, 2024 and had been its Chief Scientific Officer and Member of the Executive Man...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Andreas Pahl	CEO & Spokesman of the Executive Board	less than a year	€328.28k	sin datos
Walter Miller	Chief Financial Officer	less than a year	sin datos	sin datos
Jorg Kemkowski	Chief Operating Officer	1.3yrs	sin datos	sin datos
Sylvia Wimmer	Director Corporate Communication	no data	sin datos	sin datos
Andras Strassz	Chief Medical Officer	3.1yrs	sin datos	sin datos
George Badescu	Chief Business Officer	no data	sin datos	sin datos

1.1yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de HPHA no se considera experimentado ( 1.1 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Friedrich von Bohlen und Halbach	Member of the Supervisory Board	19yrs	€24.77k	sin datos
Georg Baur	Deputy Chairman of the Supervisory Board	24.3yrs	€40.25k	sin datos
Christof Hettich	Chairman of Supervisory Board	13.9yrs	€52.50k	sin datos
Birgit Kudlek	Member of the Supervisory Board	11.9yrs	€27.33k	sin datos
Mathias Hothum	Deputy Chairman of Supervisory Board	8.8yrs	€35.50k	sin datos
Dongzhou Liu	Member of Supervisory Board	1.8yrs	€5.08k	sin datos
Yan Xia	Member of Supervisory Board	less than a year	sin datos	sin datos

11.9yrs

Permanencia media

58.5yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de HPHA son experimentados ( 11.9 años antigüedad media).

Heidelberg Pharma Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Heidelberg Pharma Ag Announces Executive Changes

Heidelberg Pharma AG Heidelberg Pharma Expands Management Team

Heidelberg Pharma AG, Annual General Meeting, May 18, 2021

Recent updates

First quarter 2024 earnings released: €0.10 loss per share (vs €0.14 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 33% to €8.90

Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?

Heidelberg Pharma AG to Report First Half, 2024 Results on Jul 11, 2024

Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues

Price target decreased by 24% to €6.70

Third quarter 2023 earnings released: EPS: €0.002 (vs €0.14 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101

Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%

Consensus revenue estimates increase by 21%

Second quarter 2023 earnings released

Heidelberg Pharma Ag Announces Executive Changes

Price target decreased by 19% to €8.87

Consensus revenue estimates fall by 60%

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 8.0% to €10.30

Consensus forecasts updated

Consensus revenue estimates increase by 83%

Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher

Third quarter 2022 earnings released: €0.14 loss per share (vs €0.17 loss in 3Q 2021)

Second quarter 2022 earnings released: €0.04 loss per share (vs €0.22 loss in 2Q 2021)

Heidelberg Pharma AG Provides Earnings Guidance for the Year 2022

Consensus revenue estimates increase by 87%

First quarter 2022 earnings: EPS misses analyst expectations

Price target increased to €10.78

Heidelberg Pharma AG announced that it expects to receive €36 million in funding

Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma

Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely

Third quarter 2021 earnings released: €0.17 loss per share (vs €0.096 loss in 3Q 2020)

Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 in the US

CEO, CFO & Member of the Executive Management Board Jan Schmidt-Brand has left the company

Heidelberg Pharma AG Provides Financial Guidance for 2021

Forecast to breakeven in 2023

Second quarter 2021 earnings released: €0.22 loss per share (vs €0.17 loss in 2Q 2020)

Heidelberg Pharma to Present Its Proprietary ATAC Technology

Consensus revenue estimates fall to €7.56m

First quarter 2021 earnings released: €0.20 loss per share (vs €0.16 loss in 1Q 2020)

Heidelberg Pharma AG Reaffirms Earnings Guidance for 2021

Full year 2020 earnings released: €0.61 loss per share (vs €0.36 loss in FY 2019)

Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be

Heidelberg Pharma AG Provides Earnings Guidance for the Year 2021

We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

Heidelberg Pharma AG Heidelberg Pharma Expands Management Team

New 90-day high: €7.68

Heidelberg Pharma AG and Indiana University Publish Results on HER2-ATAC for Targeted Immunotherapy of Triple Negative Breast Cancer in Science Translational Medicine

Price target raised to €6.52

Heidelberg Pharma AG Announces FDA Allows the Company to Start A Phase I/IIa Clinical Trial with ATAC Candidate HDP-101

Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%

Heidelberg Pharma AG, Annual General Meeting, May 18, 2021

We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

New 90-day high: €5.94

New 90-day high: €4.90

Heidelberg Pharma AG Announces Several Presentations of Research Results on ATAC Technology At the ASH Annual Meeting 2020

Analysts update estimates

New 90-day low: €3.69

Heidelberg Pharma AG Updates Financial Guidance for the Year 2020

Third quarter earnings released

New 90-day low: €3.91

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad